SP/NK-1R系统在乳腺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2024.04.009

实用肿瘤学杂志 ›› 2024, Vol. 38 ›› Issue (4): 268-272.doi: 10.11904/j.issn.1002-3070.2024.04.009

SP/NK-1R系统在乳腺癌中的研究进展

邵禹铭¹, 朱坤兵¹ 综述, 张洁² 审校

1.青岛大学附属山东省妇幼保健院乳腺甲状腺外科(济南 250000);
2.青岛大学附属山东省妇幼保健院内科

收稿日期:2024-02-25 修回日期:2024-08-21 出版日期:2024-08-28 发布日期:2024-09-25
通讯作者: 张洁,E-mail:zhangjie19870402@163.com
作者简介:邵禹铭,男,(1986-),硕士,主治医师,从事乳腺肿瘤方面的研究。
基金资助:
山东省医学会课题专项基金(编号:YXH2021ZX052)

Research progress of SP/NK-1R system in breast cancer

SHAO Yuming¹, ZHU Kunbing¹, ZHANG Jie²

1. Department of Breast and Thyearoid Surgery,Shandong Maternal and Child Health Hospital Affiliated to Qingdao University,Jinan 250000,China;
2. Department of Internal Medicine,Shandong Maternal and Child Health Hospital Affiliated to Qingdao University

Received:2024-02-25 Revised:2024-08-21 Online:2024-08-28 Published:2024-09-25

摘要/Abstract

摘要： 近年来,尽管乳腺癌的治疗已取得诸多进展,但其发病率仍呈上升趋势,寻找新的药物靶点和生物标志物已成为研究热点。越来越多的临床研究开始关注肿瘤细胞与肿瘤微环境的相互作用,认为肿瘤微环境对恶性肿瘤的进展起着至关重要的作用。物质P(Substance P,SP)能够参与癌变过程,在维持肿瘤微环境中发挥着关键作用。NK-1受体(Neurokinin 1 receptor,NK-1R)在肿瘤细胞的细胞质中表达,与诸多肿瘤特征显著相关。SP通过其受体NK-1R诱导肿瘤细胞增殖、血管生成和迁移,并发挥抗凋亡作用。在未来的治疗方案中,能否应用NK-1R拮抗剂为乳腺癌的诊断与治疗提供更精准的靶点成为热点话题。本文就SP/NK-1R系统在乳腺癌中的研究状况进行综述。

关键词: 乳腺癌, SP/NK-1R系统, NK-1R拮抗剂, 靶向治疗

Abstract: In recent years,although many advances have been made in the treatment of breast cancer,its incidence is still on the rise,and the search for new drug targets and biomarkers has become a research hotspot.More and more clinical studies are paying attention to the interaction between tumor cells and tumor microenvironment,and it is believed that tumor microenvironment plays a crucial role in the progression of malignant tumors.Substance P(SP)can participate in the process of carcinogenesis and play a crucial key role in maintaining the tumor microenvironment.Neurokinin 1 receptor(NK-1R)is expressed in the cytoplasm of tumor cells and is significantly associated with many tumor characteristics.SP induces tumor cell proliferation,angiogenesis and migration through its receptor NK-1R,and exerts anti-apoptotic effects.In future treatment plan,whether NK-1R antagonists can be used to provide more accurate targets for the diagnosis and treatment of breast cancer has become a hot topic.This article reviews the research status of SP/NK-1R system in breast cancer.

Key words: Breast cancer, Substance P/Neurokinin 1 receptor system, Neurokinin 1 receptor antagonist, Targeted therapy

中图分类号:

R737.9

邵禹铭, 朱坤兵, 张洁. SP/NK-1R系统在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(4): 268-272.

SHAO Yuming, ZHU Kunbing, ZHANG Jie. Research progress of SP/NK-1R system in breast cancer[J]. Journal of Practical Oncology, 2024, 38(4): 268-272.

参考文献

1 Wilkinson L,Gathani T.Understanding breast cancer as a global health concern[J].Br J Radiol,2022,95(1130):20211033.
2 Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2024,74(3):229-263.
3 Muñoz M,Coveñas R.Involvement of substance P and the NK-1 receptor in cancer progression[J].Peptides,2013,48:1-9.
4 Tokuda M,Miyamoto R,Nagaoka S,et al.Substance P enhances expression of lipopolysaccharide-induce inflammatory factors in dental pulp cells[J].J Endod,2004,30(11):770-773.
5 Mehboob R,Gilani SA,Hassan A,et al.Prognostic significance of substance P/Neurokinin 1 receptor and its association with hormonal receptors in breast carcinoma[J].Biomed Res Int,2021,2021:5577820.
6 Muñoz M,Coveñas R.Involvement of substance P and the NK-1 receptor in human pathology[J].Amino Acids,2014,46(7):1727-1750.
7 徐竟捷.Neurokinin-1受体在非小细胞肺癌增殖、迁移和凋亡过程中的作用及其信号机制研究[D].兰州:兰州大学,2020.
8 Muñoz M,Coveñas R.The neurokinin-1 receptor antagonist aprepitant:an intelligent bullet against cancer?[J].Cancers(Basel),2020,12(9):2682.
9 Davoodian M,Boroumand N,Bahar MM,et al.Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer[J].Mol Biol Rep,2019,46(1):1285-1293.
10 Muñoz M,Rosso M,Coveñas R.Triple negative breast cancer:How neurokinin-1 receptor antagonists could be used as a new therapeutic approach[J].Mini Rev Med Chem,2020,20(5):408-417.
11 Muñoz M,Rosso M,Coveñas R.Neurokinin-1 receptor antagonists against hepatoblastoma[J].Cancers(Basel),2019,11(9):1258.
12 Muñoz M,González-Ortega A,Salinas-Martín MV,et al.The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer[J].Int J Oncol,2014,45(4):1658-1672.
13 Gillespie E,Leeman SE,Watts LA,et al.Truncated neurokinin-1 receptor is increased in colonic epithelial cells from patients with colitis-associated cancer[J].Proc Natl Acad Sci U S A,2011,108(42):17420-17425.
14 Zhou YL,Zhao LL,Xiong T,et al.Roles of full-length and truncated neurokinin-1 receptors on tumor progression and distant metastasis in human breast cancer[J].Breast Cancer Res Treat,2013,140(1):49-61.
15 Berger M,Neth O,Ilmer M,et al.Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo[J].J Hepatol,2014,60(5):985-994.
16 Al-Keilani MS,Elstaty RI,Alqudah MA,et al.Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index[J].PLoS One,2021,16(6):e0252616.
17 Wang F,Liu SS,Liu JQ,et al.SP promotes cell proliferation in esophageal squamous cell carcinoma through the NK1R/Hes1 axis[J].Biochem Biophys Res Commun,2019,514(4):1210-1216.
18 Ge CT,Huang HM,Huang FY,et al.Neurokinin-1 receptor is an effective oxidative stress through mitochondrial calcium overload[J].Proc Natl Acad Sci U S A,2019,116(39):19635-19645.
19 Steinhoff MS,Mentzer BV,Geppetti P,et al.Tachykinins and their receptors:contributions to physiological control and the mechanisms of disease[J].Physiol Rev,2014,94(1):265-301.
20 Garcia-Recio S,Fuster G,Fernandez-Nogueira P,et al.Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer[J].Cancer Res,2013,73(21):6424-6434.
21 Li JY,Zeng Q,Zhang YX,et al.Neurokinin-1 receptor mediated breast cancer cell migration by increased expression of MMP-2 and MMP-14[J].Eur J Cell Biol,2016,95(10):368-377.
22 Ma J,Yuan SF,Cheng JX,et al.Substance P promotes the progression of endometrial adenocarcinoma[J].Int J Gynecol Cancer,2016,26(5):845-850.
23 Deng XT,Tang SM,Wu PY,et al.SP/NK-1R promotes gallbladder cancer cell proliferation and migration[J].J Cell Mol Med,2019,23(12):7961-7973.
24 Kwatra SG,Boozalis E,Huang AH,et al.Proteomic and phosphoproteomic analysis reveals that neurokinin-1 receptor(NK1R)blockade with aprepitant in human keratinocytes activates a distinct subdomain of EGFR signaling:implications for the anti-pruritic activity of NK1R antagonists[J].Medicines(Basel),2019,6(4):114.
25 Bashash D,Safaroghli-Azar A,Bayati S,et al.Neurokinin-1 receptor(NK1R)inhibition sensitizes APL cells to anti-tumor effect of arsenic trioxide via restriction of NF-κB axis:shedding new light on resistance to aprepitant[J].Int J Biochem Cell Biol,2018,103:105-114.
26 Robinson P,Kasembeli M,Bharadwaj U,et al.Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance[J].Biomed Res Int,2016,2016:1959270.
27 Un H,Ugan RA,Kose D,et al.A novel effect of aprepitant:protection for cisplatin-induced nephrotoxicity and hepatotoxicity[J].Eur J Pharmacol,2020,880:173168.
28 Rodriguez E,Pei GS,Kim ST,et al.Substance P antagonism as a novel therapeutic option to enhance efficacy of cisplatin in triple negative breast cancer and protect PC12 cells against cisplatin-induced oxidative stress and apoptosis[J].Cancers(Basel),2021,13(15):3871.
29 Xiong J,Zhao GF,Yang SL,et al.Efficacy,tolerability and pharmacokinetic impact of aprepitant in sarcoma patients receiving ifosfamide and doxorubicin chemotherapy:a randomized controlled trial[J].Adv Ther,2019,36(2):355-364.

[1]	李倩妮, 徐灵燕, 李健, 姚雪佩, 刘美娜. 乳腺癌多维治疗质量纵向评价的趋势分析[J]. 实用肿瘤学杂志, 2024, 38(4): 213-220.
[2]	高光强, 王发琳, 李娟, 田虹, 果思伽, 于晓兰, 杨婷婷, 刘家仁. β-紫罗兰酮通过NF-κB途径抑制乳腺癌细胞增殖[J]. 实用肿瘤学杂志, 2024, 38(4): 254-261.
[3]	殷海燕, 淳志明, 马巧君, 成涵, 丁高恒, 张海燕, 刘玉琴. 2019年甘肃省肿瘤登记地区女性乳腺癌流行特征及2010-2019年趋势分析[J]. 实用肿瘤学杂志, 2024, 38(3): 141-148.
[4]	黑龙江省医学会乳腺肿瘤学组. 黑龙江省乳腺癌HER2低表达临床病理诊断专家共识(2024版)[J]. 实用肿瘤学杂志, 2024, 38(2): 71-78.
[5]	孟凡岗, 陈飞, 甄立军. DLX2对乳腺癌细胞增殖、迁移、侵袭、凋亡及乳腺癌干细胞特性的影响[J]. 实用肿瘤学杂志, 2024, 38(2): 88-95.
[6]	郑鹏飞, 董良鹏, 高延鑫, 张一夫, 秦双. 白细胞介素-38对乳腺癌患者CD8⁺T淋巴细胞功能的影响[J]. 实用肿瘤学杂志, 2024, 38(1): 30-36.
[7]	谢俊岭. 活化白细胞黏附分子在乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2024, 38(1): 45-49.
[8]	冯楚然, 曹剑钊, 陈子印, 张大昕, 鲁海玲. 乳腺癌放射性心脏损伤及其预防措施的研究进展[J]. 实用肿瘤学杂志, 2023, 37(6): 513-518.
[9]	赵诗璐, 庞达. 乳腺癌预后相关基因的生物信息学筛选与分析[J]. 实用肿瘤学杂志, 2023, 37(5): 422-428.
[10]	樊婷婷, 丁丹妮, 赵子雪, 于洋, 韩凤娟. 脂肪酸代谢与卵巢癌[J]. 实用肿瘤学杂志, 2023, 37(5): 429-433.
[11]	初思彤, 许庆勇. 三阴性乳腺癌免疫治疗耐药机制的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 449-453.
[12]	王新萍, 张自云, 王学东. 非编码RNA在乳腺癌化疗耐药中作用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(5): 454-458.
[13]	鲁泓男, 夏冰舒, 乔坤, 张世园, 黄元夕, 鲁祥石. GAS1与乳腺癌免疫治疗及药物敏感性的关系[J]. 实用肿瘤学杂志, 2023, 37(4): 351-359.
[14]	陈飞, 王颖, 曾传琴. B7-H4在乳腺癌组织中的表达及其与患者新辅助化疗后腋窝淋巴结转移的相关性分析[J]. 实用肿瘤学杂志, 2023, 37(4): 360-366.
[15]	李福程, 贾斯媛, 巴玉玲, 罗丹利, 肖敏. 免疫检查点抑制剂在早期乳腺癌新辅助治疗中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 367-371.

SP/NK-1R系统在乳腺癌中的研究进展

Research progress of SP/NK-1R system in breast cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价